Mycoplasma Testing Market Size, Share, Industry Trends and Forecast to 2030

1. Market Size & CAGR of Mycoplasma Testing market in 2021

The global mycoplasma testing market size in 2021 was valued at USD 689.24 million. With a compound annual growth rate (CAGR) of 6.18% from 2021 to 2026, the market is expected to reach USD 934.76 million by 2026. The increasing prevalence of mycoplasma infections and the growing demand for accurate diagnostic testing are the key factors driving the market growth.

2. COVID-19 Impact on the Mycoplasma Testing Market

The COVID-19 pandemic has significantly impacted the mycoplasma testing market. As healthcare systems focused on managing the pandemic, routine diagnostic testing, including mycoplasma testing, experienced disruptions. The market saw a temporary slowdown in demand for testing kits and laboratory services due to lockdowns and restrictions. However, with the gradual recovery of healthcare services, the market is expected to bounce back and witness growth in the coming years.

3. Mycoplasma Testing Dynamics

The mycoplasma testing market is driven by factors such as the increasing incidence of mycoplasma infections, rising awareness about the importance of early diagnosis, and advancements in testing technologies. The market is also influenced by factors like the availability of innovative testing solutions, government initiatives to control mycoplasma infections, and collaborations between key players to enhance testing capabilities.

4. Segments and Related Analysis

The mycoplasma testing market can be segmented based on products, technologies, applications, end-users, and regions. Product segments include testing kits, reagents, instruments, and services. Technologies encompass PCR, ELISA, direct assays, and others. Applications include cell line testing, virus testing, end-of-production cell testing, and others. End-users comprise hospitals, laboratories, pharmaceutical companies, and research institutes.

5. By Region Analysis

Regionally, the mycoplasma testing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds a significant market share due to the presence of advanced healthcare infrastructure and increased research activities. Europe follows closely, driven by technological advancements and government support. The Asia Pacific region is witnessing rapid market growth attributed to the rising prevalence of mycoplasma infections and improving healthcare facilities.

6. Key Market Players and Competitive Landscape

Key players in the mycoplasma testing market include Thermo Fisher Scientific, Charles River Laboratories, Merck KGaA, Lonza Group, PromoCell GmbH, Eurofins Scientific, Agilent Technologies, Roche Diagnostics, American Type Culture Collection (ATCC), and Sartorius AG. These companies focus on product innovation, strategic collaborations, mergers, and acquisitions to strengthen their market position and expand their product offerings.

7. Recent Happenings in the Mycoplasma Testing Market

In recent developments, Thermo Fisher Scientific launched the MycoSEQ Mycoplasma Detection Assay, a highly sensitive and reliable solution for mycoplasma testing in cell culture samples. Charles River Laboratories announced the acquisition of Vigene Biosciences, a leading provider of viral vector services for gene therapies. Merck KGaA introduced the MycoTOOL PCR Mycoplasma Detection Kit for rapid and efficient mycoplasma testing in biopharmaceutical manufacturing processes. These advancements highlight the ongoing efforts to enhance mycoplasma testing capabilities and develop innovative solutions for accurate diagnosis.